you us afternoon Good joining today. for Doug. and Thanks, thank
following dynamic of We XXXX confidence have sense extremely begin an and renewed performance introduced the energy. theory a new with we strong a year Company, for
and have growth business our substantial interest Digital core Profiler. to double-digit our returned Spatial in We GeoMx generated
a transition be into cycle expect to to we exciting us year. than company. with of that commercially both a We’re set today, product revenue of rapidly genomics in and GeoMx open-ended DSP shares a a our launched single from field our growth kick-of very a customers many month the and new will spatial growing cells genomics. characteristics we we field XXXX a accelerate up market currently defining multiplatform When is than less
review I milestones turn operating outlook before our overall results financial the current I for remarks, quarter strategic over to will objectives fourth for our then some provide During our XXXX key our highlights outlining call Tom will XXXX. performance and the for year. to and the in my on prepared
and overall eCounter I execution this of investments full paid revenue made and their of channel XXXX. service in we am in the sustain of a performance. job During to commercial XXXX. of growth extremely The We the sales product business in did that really core XXXX, our our our focus our accelerating generated and proud roughly intend growth fantastic team we in momentum improvement off growth teams and ensured XX%
of XXXX, installed During XX% more we than increase to XXX grew an our systems systems base at about eCounter year-on-year. of
continued new eCounter XX% lower-cost -- sales We to broaden for our into channel instruments eCounter smaller of with accounted sales placements. labs SPRINT
addition, XXX XX system an in strength introduced market on applications grew immunology In PanCancer number impressive markets new year. research total accounted from We our led meaningful and growth outside XXXX non-oncology results was combined of XX% XXXX. $XX million increase generated commercial sales This into XX% our XX% of last only in growth year, an we and as successfully expanded XXXX. and over the the neurology. such channel of consumable for than And XX% of new sales, more panel up remains fastest consumer oncology our by XX%, immuno-oncology our last year. The IO largest Immune also panels immunology one grew which products Panel panel. that and about we where including year Profiling neurology selling our growing by panels portfolio cancer including oncology a saw
impressive our Perhaps, research from We business. designated for parallel, delivered We was GeoMx more three the XX% more attention our of GeoMx the than preorders we our clear another eCounter and core have these instruments a achievement compelling have seen preorders of spatial of and and and XX nature customers. than expanded TAP by sites. XX% the at successfully XX objective in instruments, GeoMx of profiling Overall, leading Program excellence as centers on outside repurchased XX plus In data securing to profile, growth. great activities for customers year this from program have site installed centers distracting GeoMx is for for came areas. who projects full most focusing GeoMx momentum the X yet we product customer of build DSP completed three XXXX into momentum market with Technology Access our unseen. we and GeoMx our without hunger sign Prosigna Finally, bring advanced the successful that prelaunch
by on objective in XXXX. strategies first double-digit delivered what our in the to made growth continuing number starts is Our of business execute that new This by in us core to instruments successful eCounter a we XXXX. similar sustain eCounter to selling
being will half some about that and diversify systems. placements expect new labs oncology. to eCounter beyond of instrument bundled instruments in new strengthened sales of areas expected half XXXX we research smaller course for with GeoMx instrumental We the pace SPRINT with of once as is year and second again the The the placements eCounter of continue in the over account system
the expansion that XXXX can driver that eCounter modest growth plan of will most annualized expect account time is reps and a channel, consumable sales products can maintain to compelling focused our we $XX,XXX larger that sales installed sales on with managers be consumer delivered important channel XX% base. service who $XX,XXX the this We the per at expanded than year combination in base the of last rate and in inside key begin effective consumable adding this system sales We sales. XXXX. believe that We customer consumable eCounter of year and
we addition, leading and and fibrosis. continue of metabolism fields products, in to outside new as introducing such market with develop launching plan by experts In expanding panel into collaboration oncology
positive Society and Both Antonio, at Cancer Hematology for that select as attention presentation diagnostic decision San to base we for American NICE of Symposium. grow technology of biomarkers ASH assessment from as in revenues, such eCounter Kingdom. illustrated garner expect by continued looking the the the and driven recent meeting total signals of health identify therapy continue XX the researchers the to Breast primarily in United December to side, patients a LymphMark by to or over On abstracts in Prosigna
XXXX, Assay do study see ongoing could submissions. generate during regulatory While results from we’re which robust to not by the we expecting X be from Phase followed to LymphMark expect revenue the
second a strategic success. to trajectory launch for Spatial our is Profiler of objective GeoMx long-term Digital on Our
Over is profiling the market primary applications. last in a diverse development a years, we've we've markets. executed large and two involve comprehensive GeoMx, from convinced time, market spatial that into interest two with during The GeoMx coming for that plan become will
is and RNA where The biomarkers of is research protein spatial search for analysis first the expression. translational for the need driving
have unknown cell populations basic sequencing are to cells previously is market that target where located embraced now second discover RNA The these more discovery single-cell for within show technologies and these hungry are tissues. where scientists research will
required with the to these serve both GeoMx We of markets. have engineered capabilities
trial expand sequencers. by required samples launch ultra-high we that has discovery on protein focused throughput the intend expression and introducing flex XXXX eCounter research high hundreds RNA clinical profiling XXXX, to who officially using assays as Our of researchers value translational read the out is both FFPE system. and on provide process that GeoMx can RNA basic can an next-generation to ubiquitous GeoMx analyzed In be
single believe cell replicate most will the the Following the success we strategies popular technologies. that of
less our market profiling, While GeoMx field the this unique used the well spatial to to develops. by for and the and to and Last in at on Technology to how that Advances of Genomics to week, will believe only growing research. the will on Genome the not or researchers entry positioned the we product power market shape Meeting earlier help into the seized Inaugural the be edge capitalize we technology be introduce discovery opportunity Spatial presented GeoMx AGBT of bleeding Biology and hold Summit profile
Our and Summit accept busy early a many attendees, week. the nearly the events through whom Spatial a flew tone XXX for GeoMx in for of crowd day of a
During important across Institutes session from our morning X,XXX generated on there the which of spatial new different as few beta the RNAs data after sharing the six the plenary in tumor first highlighted their capability, during profiled Broad conference, an instruments, receiving GeoMx collaborators lab weeks types. the first
DeciBio meeting, presentation a annual GeoMx day attendees the performed this and our online profiling we was substantial XX the the Spatial three be Group simulated substantial This by by of into emerges and of total as published Over of the a theme created as in and included spatial emerging that using GeoMx months. follows researchers other XXXs leads technology. interest forward our buzz. meeting oral GeoMx of of major to AGBT by the the most technologies would of attendees at of theme mind well that front next two orders survey the over Program, presentations XXX which look GeoMx their converts in of researchers. data workshop week, presented the and Access earlier experience six getting AGBT new identified exciting customers In generated the Overall, top as the associated nearly who posters of contained differing GeoMx audience as Technology our DSP
pricing. official commercial customer unveil Meeting a Our translational and annual target during who and researchers form is take in the launch GeoMx AACR Atlanta. consumable cancer core base now place specifications, the few our weeks The the away details of focus panels and launch systems just will of eCounter will of will the
from launch TAP Mayo the by presentations at our University event customers access include Clinic. Stanford customers will and Our early
than GeoMx abstract be The review will and our publications of addition, provide GeoMx companies capabilities These a be digital by compelling Technology will platform. first build include the the In dozen that under spatial during beginning April the installations at biopharma profiling previously generated studies should illustrations unique of by and systems presented more the researchers third Program. will three academic launch upon and of the quarter. XX followed studies peer least presented data, commercial Access
the second it expect come exceptional hands that This getting look to XXXX support of beyond. an Therefore, the we position forward for success ensure will to of to leading in the While the level customers having from into pace our research even top insulation will that be us. ensure manage enjoy have priority GeoMx XXXX that service and we half institutions, be GeoMx require that of and the important experience. spending will to more to customers they of user
through beta several months, to over installations are that guide required weeks GeoMx them the a we approximately install past experiments. their found train the users During system, and its three
under the streamline expect we to bring by operate process this two system, this just per XXXX. high weeks model to we to balance touch timeline plan through to of down While XXXX, the
during of expect the XX year. book last during XX a likely to the install half that we orders incremental of received second The preorders to XXXX, we be are to GeoMx keep approximately us will on result, launch busy go GeoMx As second list XXXX. We will believe half in in wait beginning XXXX. year our revenue through accelerate and and fulfilled the to growth that the our the XXXX of
in grow which will the to estimates Given of up throughput the of we the our that critical market will it’s & commercializing skilled to & made our about in arrays launch platform our GeoMx magnitude Seq resources $X incorporated attention have about a XX-fold. received XXXX, and third is chemistry parallels in addressable strategic platform it sequencing billion entire use to objective XXXX. to the and GeoMx, which advance towards which allowed continue substantial X,XXX of Hyb to us Seq barcodes our program opportunity, commercial XXXX, And We the the deserves. invest we order increase Hyb progress. In contain to
each roughly prototype modified faster used in Our SPRINT XX times previously than has of delivered instruments proof-of-concept now instruments our XXX is studies. contractor which the manufacturer
illustrate week, a for sequence last Conference entire University at Hyb sequencing testing. of the X,XXX that highlighted collaborators progress all antibiotic applications. of to Cambridge independent field the from and the first AGBT Institutes clinical used gene, barcodes Hyb Seq-enabled and we're susceptibility they presented answer workflow. Broad key using & chemistry sample a presented data disease, oncology, technique region the Seq the our cultural & the making coding In presented we at pathogen TPXX In identification infectious our to three phenotypic studies full-skilled of where field rapid collaborators and our During the unique the
proposition HexSembler called Hyb a & & own a and genomic attention end-to-end pipeline AGBT of variance. healthy believe scientists seem rapid to that hungry alternative differentiated time. platforms landscape. & turnaround is the for Seq potential customers Seq presented NanoString's Hyb accurately and and in to market detect NGS We Hyb Seq appreciate sequencing to assemble the received value and is Finally, amount well designed understand competitive of simplicity providing novel the that analysis readout and
Seq major sample on for a progress the off displayed present Hyb we tumor focused us when panel. the during during we the XXXX, technical gene During requirements, increasing simultaneously updating you the on the Association of course of on & forward update Molecular profiled solid Pathology of The the from we’re to next fourth program on meantime, look number reducing and to In Meetings expression. future quarter and targets data platform the for use this plan calls. our refining
will QX for targets for over financial Now, to and turn XXXX. the Tom I results call our review our financial to outline